This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Resumen de acción CVET
Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Covetrus, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.99 |
| 52 Week High | US$21.20 |
| 52 Week Low | US$13.39 |
| Beta | 1.51 |
| 1 Month Change | 0.53% |
| 3 Month Change | 0.91% |
| 1 Year Change | 5.58% |
| 3 Year Change | 107.00% |
| 5 Year Change | n/a |
| Change since IPO | -50.02% |
Noticias y actualizaciones recientes
Recent updates
Covetrus GAAP EPS of -$0.03 misses by $0.06, revenue of $1.22B in-line
Aug 04Clayton, Dubilier & Rice/TPG Are Not Offering Fair Value To Covetrus Shareholders
Jun 02Covetrus, Inc.'s (NASDAQ:CVET) Intrinsic Value Is Potentially 98% Above Its Share Price
May 02
Are Investors Undervaluing Covetrus, Inc. (NASDAQ:CVET) By 40%?
Jan 07We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt
Oct 21An Intrinsic Calculation For Covetrus, Inc. (NASDAQ:CVET) Suggests It's 37% Undervalued
Sep 16Estimating The Intrinsic Value Of Covetrus, Inc. (NASDAQ:CVET)
May 31Covetrus, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Is Covetrus (NASDAQ:CVET) Using Too Much Debt?
May 05Covetrus, Inc.: Well Positioned To Enjoy Market Crosscurrents
Apr 30Who Has Been Selling Covetrus, Inc. (NASDAQ:CVET) Shares?
Feb 26We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt
Jan 22Covetrus reports Q4 net sales of prescription management business
Jan 13Covetrus (NASDAQ:CVET) Shareholders Have Enjoyed An Impressive 106% Share Price Gain
Dec 18
Covetrus, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 12Covetrus Q3 2020 Earnings Preview
Nov 09Rentabilidad de los accionistas
| CVET | US Healthcare | Mercado US | |
|---|---|---|---|
| 7D | 0.5% | 2.6% | 0.6% |
| 1Y | 5.6% | 4.4% | 25.7% |
Rentabilidad vs. Industria: CVET matched the US Healthcare industry which returned 4.9% over the past year.
Rentabilidad vs. Mercado: CVET exceeded the US Market which returned -25.8% over the past year.
Volatilidad de los precios
| CVET volatility | |
|---|---|
| CVET Average Weekly Movement | 0.3% |
| Healthcare Industry Average Movement | 7.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: CVET has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: CVET's weekly volatility has decreased from 6% to 0% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2018 | 4,873 | Ben Wolin | www.covetrus.com |
Resumen de fundamentos de Covetrus, Inc.
| Estadísticas fundamentales de CVET | |
|---|---|
| Capitalización bursátil | US$2.94b |
| Beneficios(TTM) | -US$13.00m |
| Ingresos (TTM) | US$4.65b |
0.6x
Ratio precio-ventas (PS)-226.3x
Ratio precio-beneficio (PE)¿Está CVET sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CVET | |
|---|---|
| Ingresos | US$4.65b |
| Coste de los ingresos | US$3.77b |
| Beneficio bruto | US$882.00m |
| Otros gastos | US$895.00m |
| Beneficios | -US$13.00m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.093 |
| Margen bruto | 18.97% |
| Margen de beneficio neto | -0.28% |
| Ratio deuda/patrimonio | 68.7% |
¿Cómo se ha desempeñado CVET a largo plazo?
Ver rendimiento histórico y comparativa